Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Common Equity (2016 - 2025)

Historic Common Equity for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $313.7 million.

  • Rocket Pharmaceuticals' Common Equity fell 488.28% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 488.28%. This contributed to the annual value of $463.2 million for FY2024, which is 595.65% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Common Equity of $313.7 million as of Q3 2025, which was down 488.28% from $354.2 million recorded in Q2 2025.
  • Rocket Pharmaceuticals' Common Equity's 5-year high stood at $541.1 million during Q3 2023, with a 5-year trough of $313.7 million in Q3 2025.
  • For the 5-year period, Rocket Pharmaceuticals' Common Equity averaged around $429.8 million, with its median value being $441.5 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first surged by 10081.71% in 2021, then tumbled by 3905.39% in 2024.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Common Equity stood at $454.7 million in 2021, then rose by 7.69% to $489.7 million in 2022, then rose by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then plummeted by 32.29% to $313.7 million in 2025.
  • Its last three reported values are $313.7 million in Q3 2025, $354.2 million for Q2 2025, and $412.1 million during Q1 2025.